Chronic paroxysmal hemicrania

Last updated
Chronic paroxysmal hemicrania
Other namesSjaastad syndrome
Specialty Neurology

Chronic paroxysmal hemicrania (CPH) is a severe debilitating unilateral headache usually affecting the area around the eye. It normally consists of multiple severe, yet short, headache attacks affecting only one side of the cranium. Retrospective surveys indicated that paroxysmal hemicrania was more common in women. [1] [2] However, subsequent prospective research showed an equal prevalence between females and males, with a ratio close to 1:1. [3] Unlike in migraine, it has no neurological symptoms associated with it. CPH headaches are treated through the use of non-steroidal anti-inflammatory drugs, with indomethacin found to be especially effective in eliminating symptoms.

Contents

Paroxysmal hemicrania is classified by the characteristic (high) frequency and (short) duration of attacks experienced by patients that is somewhat similar to cluster headaches, despite some important differences explained below. [4] Episodic paroxysmal hemicrania attacks occur at least twice a year and last anywhere from seven days to a year with pain free periods of a month or longer separating them. Chronic paroxysmal hemicrania attacks occur over the course of more than a year without remission or with remissions lasting less than a month. [5]

Signs and symptoms

Individuals with CPH suffer multiple short, severe headaches a day, often more than five, with most lasting between 5 and 30 minutes each. When compared to cluster headaches, CPH attacks are typically shorter. [6] Each headache is centered around the eye, temple and forehead or the back of the head and is localized to one side of the head. While redness and watering of the eye are associated with CPH, patients typically do not experience nausea or vomiting. [7] Although less common, CPH may also present as severe unilateral ear pain accompanied by autonomic symptoms. [8] Autonomic symptoms may include the presence of red ear syndrome. [9]

Attacks hit the patient many times a day, from 5 times a day up to 40 times a day with an average of 11 a day. Mild background pain can persist between attacks. They come in bouts that last from 7 days to 1 year separated by remission periods that can last more than 3 months in episodic patients, or less than 3 months in chronic patients. Onset is in adulthood and the disorder may last indefinitely or spontaneously go into remission. Circadian mechanisms are likely involved in paroxysmal hemicrania due to its highly cyclic nature. No particular circannual recurrence characterizes symptomatic periods, although some patients can experience a seasonal preponderance. [4]

Causes

The causes of paroxysmal hemicrania are ultimately still unknown. Sympathetic symptoms such as miosis and ptosis might be linked with a generalized sympathetic dysfunction. Neuropathic mechanisms may be involved, since attacks can be triggered by mechanical stimulation. Perivascular neurogenic inflammatory processes can worsen symptoms or increase pain. Dilated blood vessels may contribute in stimulating trigeminal nociceptors directly, although they cannot be the origin of pain, since even suppression of vasodilation does not stop it once it’s started. [4]

Many secondary conditions have been reported to be possible causes of CPH, according to Mehta et al., most of which are arterial abrasions or tumors. These include aneurysms in the circle of Willis, middle cerebral artery infarction, parietal arteriovenous malformation, cavernous sinus and petrous ridge meningiomas, pituitary adenoma, Pancoast tumor, gangliocytoma of the sella turcica, and malignant frontal tumors. [10] This accentuates the urgency for those diagnosed with CPH to receive an MRI head scan.[ citation needed ]

Diagnosis

The temporal branch of the facial nerve is immediately above the eye. Cranial nerve VII.svg
The temporal branch of the facial nerve is immediately above the eye.

CPH is a long-term disease with symptoms lasting for longer than a year, either without remission or with remissions that last less than a month. [5] In order to be diagnosed with CPH, a patient needs to have had at least 20 attacks filling the following criteria: [ citation needed ]

In addition, diagnosis of CPH requires that neuropathy of the supraorbital area in the temporal branch of the facial nerve be ruled out. [12]

Comparison to cluster headaches

Though outwardly similar to cluster headaches, chronic paroxysmal hemicrania is rather different, and the two headaches are not a subset of one or the other. Key differences include:

Treatments

A ten-patient study conducted by Pareja et al. found that all patients diagnosed with CPH were responsive to indomethacin and were able to completely control their symptoms. Doses of the drug ranged from 25 mg per day to 150 mg per day with a median dose of 75 mg per 24-hour period. [13] Almost all cases of CPH respond positively and effectively to indometacin, but as much as 25 percent of patients discontinued use of the drug due to adverse side effects, namely complications in the gastrointestinal tract. [14] According to a case study by Milanlioglu et al., 100 mg of lamotrigine, an antiepileptic drug, administered twice daily alleviated all painful symptoms. No side effects were noted after two months of treatment. Dosage of lamotrigine was decreased to 50 mg a day after the first two months, and no symptoms or side-effects were recorded after a three-month followup. [15]

Use of topiramate has also been found to be an effective treatment for CPH, but cluster headache medications have been found to have little effect. [12]

Epidemiology

Although CPH is often compared to cluster headaches, it is much less prevalent, occurring in only 1–3% of those who experience cluster headaches. CPH occurs roughly in 1 in 50,000 people, while cluster headaches are comparatively more common and are found in 1 in 1000 people. [5] Cluster headaches occur primarily in men, while CPH is more commonly diagnosed in women. [6] The female to male ratio of diagnosed patients can range anywhere from 1.6:1 to 2.36:1. [5] However, more recent prospective research showed an equal prevalence between females and males, with a ratio close to 1:1. [3] Symptoms may begin to appear at any age, but onset usually occurs in adulthood with a mean starting age within the thirties. [11] [16]

History

CPH was discovered by Norwegians Ottar Sjaastad and Inge Dale in 1974. The term chronic paroxysmal hemicrania was first used in 1976 by Sjaastad to describe a condition seen in two of their patients who were experiencing repeated solitary and limited daily headache attacks on only one side of the cranium. [17]

It is possible that chronic paroxysmal hemicrania was first described by Johann Oppermann in 1747 under the term "hemicranias horologica". Oppermann's report included a 35-year-old woman who had hemicranial pain that lasted for 15 minutes and recurred regularly every hour. [6]

CPH has been included in the International Headache Society's classification system since 1988. [17]

See also

Related Research Articles

<span class="mw-page-title-main">Migraine</span> Disorder resulting in recurrent moderate-severe headaches

Migraine is a genetically influenced complex neurological disorder characterized by episodes of moderate-to-severe headache, most often unilateral and generally associated with nausea and light and sound sensitivity. Other characterizing symptoms may include vomiting, cognitive dysfunction, allodynia, and dizziness. Exacerbation of headache symptoms during physical activity is another distinguishing feature. Up to one-third of migraine sufferers experience aura, a premonitory period of sensory disturbance widely accepted to be caused by cortical spreading depression at the onset of a migraine attack. Although primarily considered to be a headache disorder, migraine is highly heterogenous in its clinical presentation and is better thought of as a spectrum disease rather than a distinct clinical entity. Disease burden can range from episodic discrete attacks to chronic disease.

<span class="mw-page-title-main">Headache</span> Pain in the head, neck, or face

Headache, also known as cephalalgia, is the symptom of pain in the face, head, or neck. It can occur as a migraine, tension-type headache, or cluster headache. There is an increased risk of depression in those with severe headaches.

<span class="mw-page-title-main">Cluster headache</span> Neurological disorder

Cluster headache is a neurological disorder characterized by recurrent severe headaches on one side of the head, typically around the eye(s). There is often accompanying eye watering, nasal congestion, or swelling around the eye on the affected side. These symptoms typically last 15 minutes to 3 hours. Attacks often occur in clusters which typically last for weeks or months and occasionally more than a year.

A medication overuse headache (MOH), also known as a rebound headache, usually occurs when painkillers are taken frequently to relieve headaches. These cases are often referred to as painkiller headaches. Rebound headaches frequently occur daily, can be very painful and are a common cause of chronic daily headache. They typically occur in patients with an underlying headache disorder such as migraine or tension-type headache that "transforms" over time from an episodic condition to chronic daily headache due to excessive intake of acute headache relief medications. MOH is a serious, disabling and well-characterized disorder, which represents a worldwide problem and is now considered the third-most prevalent type of headache. The proportion of patients in the population with Chronic Daily Headache (CDH) who overuse acute medications ranges from 18% to 33%. The prevalence of medication overuse headache (MOH) varies depending on the population studied and diagnostic criteria used. However, it is estimated that MOH affects approximately 1-2% of the general population, but its relative frequency is much higher in secondary and tertiary care.

<span class="mw-page-title-main">Sumatriptan</span> Medication used for migraines & cluster headaches

Sumatriptan, sold under the brand name Imitrex among others, is a medication used to treat migraine headaches and cluster headaches. It is taken orally, intranasally, or by subcutaneous injection. Therapeutic effects generally occur within three hours.

A headache is often present in patients with epilepsy. If the headache occurs in the vicinity of a seizure, it is defined as peri-ictal headache, which can occur either before (pre-ictal) or after (post-ictal) the seizure, to which the term ictal refers. An ictal headache itself may or may not be an epileptic manifestation. In the first case it is defined as ictal epileptic headache or simply epileptic headache. It is a real painful seizure, that can remain isolated or be followed by other manifestations of the seizure. On the other hand, the ictal non-epileptic headache is a headache that occurs during a seizure but it is not due to an epileptic mechanism. When the headache does not occur in the vicinity of a seizure it is defined as inter-ictal headache. In this case it is a disorder autonomous from epilepsy, that is a comorbidity.

<span class="mw-page-title-main">Triptan</span> Class of pharmaceutical drugs

Triptans are a family of tryptamine-based drugs used as abortive medication in the treatment of migraines and cluster headaches. This drug class was first commercially introduced in the 1990s. While effective at treating individual headaches, they do not provide preventive treatment and are not considered a cure. They are not effective for the treatment of tension–type headache, except in persons who also experience migraines. Triptans do not relieve other kinds of pain.

<span class="mw-page-title-main">Indometacin</span> Anti-inflammatory drug

Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.

Sexual headache is a type of headache that occurs in the skull and neck during sexual activity, including masturbation or orgasm. These headaches are usually benign, but occasionally are caused by intracranial hemorrhage and cerebral infarction, especially if the pain is sudden and severe. They may be caused by general exertion, sexual excitement, or contraction of the neck and facial muscles. Most cases can be successfully treated with medication.

Hemicrania continua (HC) is a persistent unilateral headache that responds to indomethacin. It is usually unremitting, but rare cases of remission have been documented. Hemicrania continua is considered a primary headache disorder, meaning that another condition does not cause it.

Persistent aura without infarction (PAWOI) is a rare and seemingly benign condition, first described in case reports in 1982 as "prolonged/persistent migraine aura status", and in 2000 as "migraine aura status", that is not yet fully understood. PAWOI is said to possibly be a factor involved in a variety of neurological symptoms, including visual snow, loss of vision, increased afterimages, tinnitus, and others. The pathogenesis of PAWOI is unknown. It is not clear which medical examinations are useful in diagnosing PAWOI. At present, PAWOI is usually diagnosed solely based on the patient's current and past symptoms. It is possible that an "overactive brain" or a chemical imbalance underlies the disorder. Various medications have been tried as treatment, notably acetazolamide, valproate, lamotrigine, topiramate, and furosemide.

Migraine surgery is a surgical operation undertaken with the goal of reducing or preventing migraines. Migraine surgery most often refers to surgical nerve decompression of one or several nerves in the head and neck which have been shown to trigger migraine symptoms in many migraine sufferers. Following the development of nerve decompression techniques for the relief of migraine pain in the year 2000, these procedures have been extensively studied and shown to be effective in appropriate candidates. The nerves that are most often addressed in migraine surgery are found outside of the skull, in the face and neck, and include the supra-orbital and supra-trochlear nerves in the forehead, the zygomaticotemporal nerve and auriculotemporal nerves in the temple region, and the greater occipital, lesser occipital, and third occipital nerves in the back of the neck. Nerve impingement in the nasal cavity has additionally been shown to be a trigger of migraine symptoms.

Hypnic headaches are benign primary headaches that affect the elderly, with an average age of onset at 63 ± 11 years. They are moderate, throbbing, bilateral or unilateral headaches that wake the sufferer from sleep once or multiple times a night. They typically begin a few hours after sleep begins and can last from 15–180 min. There is normally no nausea, photophobia, phonophobia or autonomic symptoms associated with the headache. They commonly occur at the same time every night possibly linking the headaches with circadian rhythm, but polysomnography has recently revealed that the onset of hypnic headaches may be associated with REM sleep.

<span class="mw-page-title-main">Mollaret's meningitis</span> Medical condition

Mollaret's meningitis is a recurrent or chronic inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. Since Mollaret's meningitis is a recurrent, benign (non-cancerous), aseptic meningitis, it is also referred to as benign recurrent lymphocytic meningitis. It was named for Pierre Mollaret, the French neurologist who first described it in 1944.

Vestibular migraine (VM) is vertigo with migraine, either as a symptom of migraine or as a related neurological disorder.

Preventive treatment of migraine can be an important component of migraine management. The goals of preventive therapy are to reduce the frequency, painfulness, and/or duration of migraine attacks, and to increase the effectiveness of abortive therapy. Another reason to pursue prevention is to avoid medication overuse headache (MOH), otherwise known as rebound headache, which can arise from overuse of pain medications, and can result in chronic daily headache. Preventive treatments of migraine include medications, nutritional supplements, lifestyle alterations, and surgery. Prevention is recommended in those who have headaches more than two days a week, cannot tolerate the medications used to treat acute attacks, or those with severe attacks that are not easily controlled.

Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing is a rare headache disorder that belongs to the group of headaches called trigeminal autonomic cephalalgia (TACs). Symptoms include excruciating burning, stabbing, or electrical headaches mainly near the eye and typically these sensations are only on one side of the body. The headache attacks are typically accompanied by cranial autonomic signs that are unique to SUNCT. Each attack can last from five seconds to six minutes and may occur up to 200 times daily.

Abdominal migraine(AM) is a functional disorder that usually manifests in childhood and adolescence, without a clear pathologic mechanism or biochemical irregularity. Children frequently experience sporadic episodes of excruciating central abdominal pain accompanied by migrainous symptoms like nausea, vomiting, severe headaches, and general pallor. Abdominal migraine can be diagnosed based on clinical criteria and the exclusion of other disorders.

Occipital nerve stimulation (ONS), also called peripheral nerve stimulation (PNS) of the occipital nerves, is used to treat chronic migraine patients who have failed to respond to pharmaceutical treatments.

Trigeminal autonomic cephalalgia (TAC) refers to a group of primary headaches that occurs with pain on one side of the head in the trigeminal nerve area and symptoms in autonomic systems on the same side, such as eye watering and redness or drooping eyelids.

References

  1. ↑ Antonaci, Fabio; Sjaastad, Ottar (November 1989). "Chronic Paroxysmal Hemicrania (CPH): A Review of the Clinical Manifestations". Headache: The Journal of Head and Face Pain. 29 (10): 648–656. doi:10.1111/j.1526-4610.1989.hed2910648.x. ISSN   0017-8748. PMID   2693408.
  2. ↑ Boes, Christopher J.; Dodick, David W. (September 2002). "Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients". Headache. 42 (8): 699–708. doi:10.1046/j.1526-4610.2002.02171.x. ISSN   0017-8748. PMID   12390632.
  3. 1 2 Cittadini, Elisabetta; Matharu, Manjit S.; Goadsby, Peter J. (April 2008). "Paroxysmal hemicrania: a prospective clinical study of 31 cases". Brain: A Journal of Neurology. 131 (Pt 4): 1142–1155. doi:10.1093/brain/awn010. ISSN   1460-2156. PMID   18252775.
  4. 1 2 3 Butticè, Claudio (2022). What you need to know about headaches. Santa Barbara, California: Greenwood Publishing Group. ISBN   978-1-4408-7531-1. OCLC   1259297708.
  5. 1 2 3 4 Goadsby, Peter J., Stephen D. Silberstein, and David Dodick. "Chronic Paroxysmal Hemicrania". Chronic Daily Headache for Clinicians. Hamilton, Ont.: BC Decker, 2005. N. pag. Print.
  6. 1 2 3 4 Eadie, Mervyn J. "Chronic Paroxysmal Hemicrania". Headache: Through the Centuries. New York: Oxford UP, 2012. 222-24. Print.
  7. ↑ "Michigan Headache and Neurological Institute - Chronic Paroxysmal Hemicrania" . Retrieved 19 March 2014.
  8. ↑ Boes, Christopher J.; Swanson, Jerry W.; Dodick, David W. (1998). "Chronic Paroxysmal Hemicrania Presenting as Otalgia With a Sensation of External Acoustic Meatus Obstruction: Two Cases and a Pathophysiologic Hypothesis". Headache: The Journal of Head and Face Pain. 38 (10): 787–791. doi: 10.1046/j.1526-4610.1998.3810787.x . ISSN   1526-4610. PMID   11279905. S2CID   39787599.
  9. ↑ Lambru, Giorgio; Miller, Sarah; Matharu, Manjit S (2013). "The red ear syndrome". The Journal of Headache and Pain. 14 (1): 83. doi: 10.1186/1129-2377-14-83 . ISSN   1129-2369. PMC   3850925 . PMID   24093332.
  10. ↑ Mehta, Noshir R., George E. Maloney, Dhirendra S. Bana, and Steven J. Scrivani. "Head, Face, and Neck Pain: Science, Evaluation, and Management: An Interdisciplinary Approach". Hoboken, NJ: Wiley, 2009. Print.
  11. 1 2 "IHS - Chronic Paroxysmal Hemicrania". Archived from the original on 21 September 2013. Retrieved 19 March 2014.
  12. 1 2 Jay, Gary W. The Headache Handbook: Diagnosis and Treatment. Boca Raton: CRC, 1998. Print.
  13. ↑ Pareja, Ja, Ab Caminero, E. Franco, Jl Casado, J. Pascual, and M. Sanchez Del Ri'o. "Dose, Efficacy and Tolerability of Long-term Indomethacin Treatment of Chronic Paroxysmal Hemicrania and Hemicrania Continua". Cephalalgia. 21.9 (2001): 906-10. Print.
  14. ↑ Camarda, Cecilia, Rosolino Camarda, and Roberto Monastero. "Chronic Paroxysmal Hemicrania And Hemicrania Continua Responding To Topiramate: Two Case Reports". Clinical Neurology & Neurosurgery. 100.1 (2008): 88-91. Academic Search Complete. Web. 27 Feb. 2014.
  15. ↑ Milanlioglu, A., T. Tombul, and R. Sayin. "Chronic Paroxysmal Hemicrania Responsive to Lamotrigine". Pakistan Journal of Medical Sciences. 27.2 (2011): 456-57. Web.
  16. ↑ "The Migraine Trust - Paroxysmal Hemicrania". Archived from the original on 24 March 2014. Retrieved 20 March 2014.
  17. 1 2 "Medscape - Chronic Paroxysmal Hemicrania" . Retrieved 20 March 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.